Hiding in Plain Sight – Identify APOL1-Mediated Kidney Disease†
Identify APOL1 variants associated with APOL1-mediated kidney disease (AMKD) with Renasight™ sponsored renal genetic testing for eligible* patients of African ancestry††
Black Americans are 4 times more likely to develop kidney failure compared to other populations, raising the possibility of an underlying genetic contribution to this disparity1,2
Genetic testing is a critical first step—genetic testing is the only way to confirm if a patient has AMKD.
Vertex Pharmaceuticals is sponsoring a no-cost Renasight™ renal genetic testing for eligible* patients of African ancestry diagnosed with chronic kidney disease††
Support at Every Step
When you order Renasight™, you have access to a team of highly dedicated doctors, therapeutic specialists, and licensed genetic counselors committed to making Renasight™ a simple and seamless process from ordering, to results, to patient education.
Complementary Genetic Counseling
Natera’s Renal Genetic Counselors (RGC’s) are trained and certified to provide genetic counseling, education, and support to clinicians, patients, and/or families who have been, or plan to be, tested with Renasight™. Our RGC’s work to provide the highest level of support to you as well as your patients and families.
RGCs services include:
- Help providers better understand individual Renasight™ test results
- Help patients better understand their Renasight™ test results, with post RGC session notes given to providers to add to patient charts
- Explain how gene changes can cause genetic conditions
- Talk about the inheritance pattern of genetic conditions for patients/families
- Inform clinicians when a Variant of Uncertain Significance (VUS) has been reclassified
- Inform clinicians in the event that a Renasight™ test result has changed because of a variant upgrade due to reclassification
- Provide support and resources
Nurse Coordinator Team
Natera’s Nurse Coordinator team offers additional support to you and your staff when placing Renasight™ orders, fulfilling Renasight™ kits, answering requisition form questions, tracking and receiving results, and coordinating blood draws.
Learn more about the sponsored Renasight™ genetic testing program
Select your user type to proceed!
† APOL1-mediated kidney disease as well as other genetic kidney disease diagnoses can only be made by a healthcare provider when taking into consideration all patient health information, including genetic testing results
†† The Sponsored Renasight™ Genetic Testing Program is funded by Vertex Pharmaceuticals Incorporated. Additional terms and conditions apply. This program is subject to change or discontinuation without notice.
Eligible patients and healthcare providers have no expectations or obligations to Natera or Vertex Pharmaceuticals to participate in the sponsored Renasight™ Genetic Testing Program.
All tests must be ordered by a qualified healthcare provider based on clinical necessity for the patient. Healthcare providers must also confirm patient eligibility criteria for the sponsored Renasight™ Genetic Testing Program and complete a signed attestation form for each patient.
Natera never distributes identifiable patient data or information. Natera will never share identifiable patient data or information. Vertex Pharmaceuticals and third parties may receive aggregated, de-identified data, and contact information for healthcare providers that participate in this sponsored Renasight™ genetic testing program.
References
1Umeukeje EM, Young BA. Genetics and ESKD Disparities in African Americans. Am J Kidney Dis. 2019 Dec;74(6):811-821. doi: 10.1053/j.ajkd.2019.06.006. Epub 2019 Oct 10. PMID: 31606237; PMCID: PMC7373097.
2https://www.niddk.nih.gov/health-information/kidney-disease/race-ethnicity
3Elliott MD et al. J Am Soc Nephrol. 2023;34(5):909-919